Stock NTRA NATERA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Natera, Inc.

Equities

NTRA

US6323071042

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-03 pm EDT 		5-day change 1st Jan Change
96.98 USD +3.48% Intraday chart for Natera, Inc. +5.80% +54.82%
May. 01 Natera, Inc. Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage CI
Apr. 18 Natera Insider Sold Shares Worth $7,265,651, According to a Recent SEC Filing MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
BU
Natera to Report its First Quarter 2024 Results on May 9
BU
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
BU
Natera, Inc. Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
CI
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
BU
Natera Insider Sold Shares Worth $7,265,651, According to a Recent SEC Filing
MT
Natera Insider Sold Shares Worth $634,797, According to a Recent SEC Filing
MT
Goldman Sachs Adjusts Natera Price Target to $100 From $90, Maintains Buy Rating
MT
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
BU
Natera, Inc. Announces Publication of Larger Prospective dd-cfDNA Study in Kidney Transplantation
CI
Natera Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heart dd-cfDNA Test for Heart Transplant Recipients
AQ
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
BU
Natera, Inc. Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heartd-cfDNA Test for Heart Transplant Recipients
CI
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
AQ
North American Morning Briefing : Inflation Data, -2-
DJ
Natera Reports Positive Surveillance Analysis From Phase 3 Study of Bladder Cancer Test; Shares Rise
MT
Bernstein Upgrades Natera to Outperform From Market Perform, Raises Price Target to $120 From $86
MT
Natera Insider Sold Shares Worth $2,468,822, According to a Recent SEC Filing
MT
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
BU
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103, A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NTRA Stock
  4. News Natera, Inc.